ImmunityBio (IBRX)
(Delayed Data from NSDQ)
$3.52 USD
+0.04 (1.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.52 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for ImmunityBio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 266 | 107 | 317 | 66 | 52 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 28 | 33 | 17 | 9 | 4 |
Total Current Assets | 294 | 141 | 334 | 76 | 56 |
Net Property & Equipment | 146 | 144 | 83 | 54 | 61 |
Investments & Advances | 1 | 6 | 1 | 8 | 11 |
Other Non-Current Assets | 7 | 7 | 6 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 17 | 20 | 1 | 0 | 0 |
Deposits & Other Assets | 3 | 0 | 7 | 1 | 4 |
Total Assets | 504 | 362 | 469 | 152 | 143 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 432 | 299 | 0 | 0 |
Accounts Payable | 9 | 21 | 11 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 43 | 42 | 51 | 8 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 3 | 4 | 7 | 4 |
Total Current Liabilities | 58 | 501 | 369 | 25 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 577 | 241 | 0 | 0 | 0 |
Long-Term Debt | 105 | 0 | 306 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 311 | 22 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,090 | 812 | 713 | 34 | 22 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,375 | 1,931 | 1,720 | 872 | 783 |
Retained Earnings | -2,962 | -2,378 | -1,962 | -755 | -662 |
Other Equity | 1 | -2 | -2 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -586 | -450 | -244 | 117 | 121 |
Total Liabilities & Shareholder's Equity | 504 | 362 | 469 | 152 | 143 |
Total Common Equity | -586 | -450 | -244 | 117 | 121 |
Shares Outstanding | 667.70 | 400.30 | 397.60 | 109.00 | 98.30 |
Book Value Per Share | -0.88 | -1.12 | -0.61 | 1.08 | 1.23 |
Fiscal Year End for ImmunityBio, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 218 | 171 | 266 | 190 | 46 |
Receivables | 1 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 0 | 0 | 0 | 0 |
Other Current Assets | 22 | 25 | 28 | 25 | 21 |
Total Current Assets | 243 | 196 | 294 | 215 | 67 |
Net Property & Equipment | 142 | 144 | 146 | 152 | 151 |
Investments & Advances | 0 | 0 | 1 | 1 | 1 |
Other Non-Current Assets | 7 | 7 | 7 | 7 | 7 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 16 | 17 | 17 | 18 | 19 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 4 |
Total Assets | 444 | 401 | 504 | 432 | 291 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 37 |
Accounts Payable | 20 | 14 | 9 | 20 | 25 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 482 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 35 | 33 | 43 | 65 | 62 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 1 | 1 | 1 |
Total Current Liabilities | 62 | 54 | 58 | 90 | 613 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 584 | 580 | 577 | 194 | 250 |
Long-Term Debt | 109 | 107 | 105 | 480 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 350 | 311 | 40 | 28 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,142 | 1,092 | 1,090 | 843 | 936 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,532 | 2,404 | 2,375 | 2,316 | 1,991 |
Retained Earnings | -3,230 | -3,096 | -2,962 | -2,728 | -2,633 |
Other Equity | 1 | 1 | 1 | 2 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -697 | -691 | -586 | -411 | -645 |
Total Liabilities & Shareholder's Equity | 444 | 401 | 504 | 432 | 291 |
Total Common Equity | -697 | -691 | -586 | -411 | -645 |
Shares Outstanding | 691.50 | 677.00 | 667.70 | 667.70 | 440.60 |
Book Value Per Share | -1.01 | -1.02 | -0.88 | -0.62 | -1.46 |